CGS 26303

CGS 26303 is an endothelin-converting enzyme (ECE) inhibitor. CGS 26303 increases the expression of endothelin-converting enzyme-1 in endothelial cells. CGS 26303 attenuates cerebral vasospasm in a rabbit subarachnoid hemorrhage model. CGS 26303 improves birth survival and alleviates pulmonary hypoplasia in newborn rats in a rat model of congenital diaphragmatic hernia. CGS 26303 can be used for research on cardiovascular and cerebrovascular diseases and congenital diaphragmatic hernia[1][2][3].

Product Specifications

CAS Number

[154116-31-1]

UNSPSC

12352005

Target

Endothelin-Converting Enzyme (ECE)

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Smiles

O=P(O)(O)CN[C@H](C1=NN=NN1)CC2=CC=C(C3=CC=CC=C3)C=C2

Molecular Formula

C16H18N5O3P

Molecular Weight

359.32

References & Citations

[1]Raoch V, et alS. The peptidase inhibitor CGS-26303 increases endothelin converting enzyme-1 expression in endothelial cells through accumulation of big endothelin-1. Br J Pharmacol. 2007 Oct;152 (3) :313-22. |[2]Kwan AL, et al. Continuous intravenous infusion of CGS 26303, an endothelin-converting enzyme inhibitor, prevents and reverses cerebral vasospasm after experimental subarachnoid hemorrhage. Neurosurgery. 2001 Aug;49 (2) :422-7; discussion 427-9. d|[3]Kavanagh M, et al. Effect of CGS 26303, an endothelin-converting enzyme-neutral endopeptidase inhibitor, on nitrofen-induced congenital diaphragmatic hernia in the rat. J Pediatr Surg. 2000 May;35 (5) :780-4.